NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that management will present at two upcoming investment conferences:

  • RHK Capital 4th Annual Disruptive Growth Conference on Thursday, September 5 at 11:00 a.m. Eastern time. The conference is being hosted by Reed Smith LLP in New York City;
  • Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24 at 1:30 p.m. Eastern time. The conference is being held at the Sofitel New York Hotel.

“We are eager to share the early success of our new commercialization strategy for Avenova that is aimed at increasing product accessibility, enhancing the patient experience, and maintaining product affordability,” said Justin Hall, NovaBay CEO. “We have improved the efficiency of both our prescription sales and direct sales channels, and just recently launched Avenova Direct on, making prescription-strength Avenova available for the first time without a prescription.

“We are preparing for another direct-to-consumer launch later this year for CelleRx, our product for aesthetic dermatology,” he added. “This unique topical solution based on our pure hypochlorous formulation, which is especially designed to gently clean and ease discomfort following cosmetic procedures, targets a large global market opportunity.”

The corporate presentation for these events will be available on the Investors section of the Company's website.

About Avenova®

Avenova is an eye care product formulated with our proprietary, stable and pure form of hypochlorous acid. Avenova is designed for removal of the microorganisms and debris that contribute to conditions such as meibomian gland dysfunction, dry eye and blepharitis. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce and available online direct-to-consumer through

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Socialize and Stay informed on NovaBay’s progress Like us on Facebook Follow us on Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s Website

Avenova Purchasing Information For NovaBay Avenova purchasing information: Please call 800-890-0329 or email

NovaBay Contact Justin Hall President and Chief Executive Officer 510-899-8800

Investor Contact LHA Investor Relations Jody Cain 310-691-7100

NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more NovaBay Pharmaceuticals Charts.
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more NovaBay Pharmaceuticals Charts.